AlfaKinetic
by Anervea
LandscapeMonitorCompareProfileAsk
principle

Nothing is shown without a source. When the data can’t answer, the product says so.

LB Pharmaceuticals
tenant
person

Medical Director Clinical Science

as of 2026-07-01
Monitor thisAsk about this
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Takeda
Roles
Study Director
Trial investigator
no

Trials led

3
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
NCT03319953Phase 2Completed
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
NCT02748694Phase 1Completed
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
NCT02079844Phase 1Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
trial
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
trial
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
trial